| 陈飞燕,许建义,林 泓.舒眠胶囊联合喹硫平对精神分裂症患者阴性症状、睡眠质量及神经递质的影响[J].,2025,(18):2973-2980 |
| 舒眠胶囊联合喹硫平对精神分裂症患者阴性症状、睡眠质量及神经递质的影响 |
| Influence of Shumian Capsules Combined with Quetiapine on Negative Symptoms, Sleep Quality and Neurotransmitters in Patients with Schizophrenia |
| 投稿时间：2025-04-10 |
| DOI：10.13241/j.cnki.pmb.2025.18.013 |
| 中文关键词: 舒眠胶囊 喹硫平 精神分裂症 阴性症状 睡眠质量 神经递质 |
| 英文关键词: Shumian Capsules Quetiapine Schizophrenia Negative symptoms Sleep quality Neurotransmitters |
| 基金项目: |
|
| 摘要点击次数: 212 |
| 全文下载次数: 110 |
| 中文摘要: |
| 摘要 目的：探讨舒眠胶囊联合喹硫平对精神分裂症患者阴性症状、睡眠质量及神经递质的影响。方法：回顾性选取福建省福州市鼓楼区医院2022年4月至2024年5月期间收治的50例精神分裂症患者为研究组，按1: 1匹配病例原则选取同期50例精神分裂症患者为参照组。参照组接受喹硫平治疗，研究组在参照组的基础上联合舒眠胶囊治疗。对比两组阴性症状量表（negative symptom scale, SANS）、阳性和阴性症状量表（positive and negative symptom scale, PANSS）、匹兹堡睡眠质量指数（Pittsburgh sleep quality index, PSQI）、社会功能评定量表（social-skills for psychiatric inpatients, SSPI）、副反应量表（treatment emergent symptom scale, TESS）、焦虑自评量表（self-rating anxiety scale, SAS）、抑郁自评量表（self-rating depression scale, SDS）评分、神经递质[γ-氨基丁酸（γ-aminobutyric acid, GABA）、脑源性神经营养因子（brain-derived neurotrophic factor, BDNF）、谷氨酸（glutamic acid, Glu）]水平和不良反应发生情况。结果：两组治疗4周后、治疗8周后SANS、PANSS、PSQI、TESS、SAS、SDS评分和Glu水平下降，且研究组低于参照组；SSPI评分和GABA、BDNF水平升高，且研究组高于参照组（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：舒眠胶囊联合喹硫平可有效改善精神分裂症患者阴性症状、睡眠质量及神经递质，且安全性较好。 |
| 英文摘要: |
| ABSTRACT Objective: This prospective study is conducted to explored the influence of Shumian Capsules combine with quetiapine on negative symptoms, sleep quality and neurotransmitters in patients with schizophrenia. Methods: 50 patients with schizophrenia admitted to Fuzhou Gulou District Hospital of Fujian Province from April 2022 to May 2024 were retrospectively selected as the study group. According to the principle of 1: 1 matching cases, 50 patients with schizophrenia in the same period were selected as the reference group. Reference group received quetiapine treatment, while study group was treated with Shumian capsules on the basis of the reference group. Negative symptom scale (SANS), positive and negative symptom scale (PANSS), Pittsburgh sleep quality index (PSQI), social-skills for psychiatric inpatients (SSPI), treatment emergent symptom scale (TESS), self-rating anxiety scale SAS), self-rating depression scale (SDS) score, neurotransmitter levels [γ-aminobutyric acid (GABA) , brain-derived neurotrophic factor (BDNF), glutamic acid (Glu) and the occurrence of adverse reactions were compared between the two groups. Results:: The scores of SANS, PANSS, PSQI, TESS, SAS, SDS and Glu levels decreased 4 weeks and 8 weeks after treatment in both groups, and study group were lower than those in reference group, SSPI score and GABA and BDNF levels increased, and study group were higher than those in the reference group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Shumian Capsules combined with quetiapine can effectively improve negative symptoms, sleep quality and neurotransmitters in patients with schizophrenia, and have good safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
